Phase III ARTEMIS-008 Trial Shows Risvutatug Rezetecan Significantly Improves Overall Survival in Relapsed Small-Cell Lung Cancer
B7-H3-directed antibody-drug conjugate reduced the risk of death by 54% compared with topotecan and improved progression-free survival and response rates SEOUL, South Korea, Sept. 13, 2026 /PRNewswire/ -- Results from the randomized Phase III ARTEMIS-008 trial show that risvutatug...
Short extract only — this publisher licenses its text. Read the full release at the source.
More from Commercial newswire
- TimberHP EPDs Document Carbon Storage Across Complete Wood Fiber Insulation Portfolio
- LG Energy Solution's Battery Energy Storage System Qualifies as NVIDIA DSX Ready BESS
- C&C Branding Launches Titan Sound℠, a New Leadership Branding Offering
The rest of this wire is for subscribers
Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
7 days, no card required.
Read releases like this the second they cross the wire.
1,200+ — live on PPN World right now. Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
Start the free trial →Your announcement next? Distribute your press release to the global wires with PPN Source — and track its pickup live here.
PPN Source →